ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1232

Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation

Richard Reynolds1, Tony Merriman 2, Alexander Szalai 3, Nicholas Sumpter 4, S Louis Bridges 5 and Jeffrey Edberg 1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Otago, Birmingham, AL, 3University of Alabama, Birmingham, AL, 4University of Otago, Birmingham, 5University of Alabama at Birmingham, Birmingham

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: gout and Gene Expression

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The transcriptomic changes accompanying the transition from asymptomatic hyperuricemia to gout are currently unknown but may be important for identifying and understanding important molecular triggers of gout. We tested the hypothesis that gene expression differences would be seen between whole blood from individuals with gout versus normouricemic and hyperuricemic (non-gout) controls.

Methods: Peripheral blood samples were collected (directly into PAXgene RNA tubes) from 13 gout patients, 3 normuricemic and 3 hyperuricemic controls from the gout Rheumatology Database and Repository (RADAR) at the University of Alabama at Birmingham. Whole blood mRNA was isolated using poly A selection and the transcriptome was sequenced. Sequences were quality controlled and then aligned to the genome using the Spliced Transcripts Alignment to a Reference (STAR) software package.  We tested for fold change differences in mRNA content between controls and gout cases using the R statistical computing package DESeq2.

Results: RNA sequencing yielded an average of 25 M reads per sample with an average read length of 125 bases. Forty eight gene transcripts were significantly differentially expressed (P value < 0.05), after correction for multiple testing, between gout cases and controls (normouricemic plus hyperuricemic). Of these differentially expressed gene transcripts, six that were overexpressed in gout compared to controls (Transcobalamin 1-TCN1, Amine oxidase-AOC1, Matrix metallopeptidase 8-MMP8, Cysteine rich secretory protein 3-CRISP3, Secretory leukocyte peptidase inhibitor-SLPI and Olfactomedin 4-OLFM4) are known to be involved in neutrophil degranulation. Another notable transcript significantly upregulated in gout cases was the S100 calcium binding protein A8-S100A8, which is associated with the production of reactive oxygen species (ROS). Transmembrane protein 176B-TMEM176B, was significantly downregulated in gout cases compared to controls.

Conclusion: The upregulation of genes that implicate pathways representing neutrophil biology (degranulation and ROS production) is consistent with the known role of neutrophils in gout pathogenesis. It is possible that this reflects true differences in the neutrophil gene expression program of gout-affected individuals compared to hyperuricemic and/or normouricemic controls. Reduced expression of TMEM176B has been shown to associate with activation of the NLRP3 inflammasome. Our whole transcriptomic study in gout patients and controls highlights the central role of inflammatory cell activation in the pathogenesis of gout.


Disclosure: R. Reynolds, None; T. Merriman, Ardea Biosciences, 2, 5, AstraZeneca, 2, 5, Ironwood Pharmaceuticals, 2; A. Szalai, None; N. Sumpter, None; S. Bridges, None; J. Edberg, None.

To cite this abstract in AMA style:

Reynolds R, Merriman T, Szalai A, Sumpter N, Bridges S, Edberg J. Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/whole-blood-rna-sequencing-study-of-gout-cases-and-controls-demonstrates-transcriptomic-differences-with-relevance-to-inflammatory-cell-activation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-blood-rna-sequencing-study-of-gout-cases-and-controls-demonstrates-transcriptomic-differences-with-relevance-to-inflammatory-cell-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology